We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

128 hedge funds and large institutions have $369M invested in Keryx Biopharmaceuticals Inc in 2015 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 42 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more capital invested

Capital invested by funds: $313M → $369M (+$56.5M)

7% less funds holding

Funds holding: 138128 (-10)

12% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 42

31% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 32

38% less call options, than puts

Call options by funds: $4.4M | Put options by funds: $7.14M

Holders
128
Holders Change
-10
Holders Change %
-7.25%
% of All Funds
3.36%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
22
Increased
37
Reduced
42
Closed
32
Calls
$4.4M
Puts
$7.14M
Net Calls
-$2.74M
Net Calls Change
-$733K
Name Holding Trade Value Shares
Change
Change in
Stake
BG
1
Baupost Group
Massachusetts
$130M
Vanguard Group
2
Vanguard Group
Pennsylvania
$30.3M -$5.29M -1,112,591 -16%
ACM
3
Abrams Capital Management
Massachusetts
$27.8M +$2.38M +500,000 +10%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$22.4M -$261K -55,005 -1%
State Street
5
State Street
Massachusetts
$20.1M -$13.6M -2,867,944 -42%
BIT
6
BlackRock Institutional Trust
California
$13.2M +$361K +76,006 +3%
BFA
7
BlackRock Fund Advisors
California
$13M +$519K +109,250 +4%
Norges Bank
8
Norges Bank
Norway
$9.15M +$4.13M +870,000 +92%
CCP
9
Clough Capital Partners
Massachusetts
$8.6M +$336K +70,800 +4%
Ameriprise
10
Ameriprise
Minnesota
$8.58M +$7.25M +1,526,094 +878%
RPAM
11
Rhenman & Partners Asset Management
Sweden
$6.23M -$1.57M -330,000 -21%
Northern Trust
12
Northern Trust
Illinois
$5.86M +$135K +28,344 +3%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$5.16M +$238K +50,035 +5%
Millennium Management
14
Millennium Management
New York
$4.75M +$4.28M +901,827 +2,283%
RHJA
15
Rice Hall James & Associates
California
$4.38M +$1.66M +350,340 +68%
Franklin Resources
16
Franklin Resources
California
$4.22M -$20.1M -4,226,228 -83%
PI
17
Putnam Investments
Massachusetts
$3.4M
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.35M +$31.9K +6,711 +1%
CCM
19
Cadian Capital Management
New York
$3.03M
BGIM
20
Brandywine Global Investment Management
Pennsylvania
$2.48M +$2.25M +472,740 +2,674%
UBS Group
21
UBS Group
Switzerland
$2.35M -$58K -12,203 -3%
CWG
22
C WorldWide Group
Denmark
$2.13M
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$1.93M +$1.12M +235,311 +161%
Bank of America
24
Bank of America
North Carolina
$1.9M -$1.36M -286,545 -43%
Charles Schwab
25
Charles Schwab
California
$1.9M +$63.7K +13,405 +4%

KERX Hedge Fund Activity: Q4 2015 in Review

128 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2015, worth a combined $369M — up 18% from $313M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of KERX and 22 opened new positions — a net loss of 10 holders — while 42 trimmed existing stakes and 37 added.

The largest buyer was Ameriprise, adding an estimated $7.25M. The largest seller was Franklin Resources, cutting an estimated $20.1M.

  • 128 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2015, down from 138 in Q3 2015.
  • Funds reported $369M of Keryx Biopharmaceuticals Inc stock for Q4 2015, up 18% quarter-over-quarter.
  • 22 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2015 and 32 closed out, a net change of -10 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q4 2015 was Ameriprise, an estimated $7.25M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q4 2015 was Franklin Resources, an estimated $20.1M sold.

Based on aggregated 13F filings for Q4 2015.